This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kono, K. Articles by Matsumoto, Y. Search for Related Content PubMed PubMed Citation Articles by Kono, K. Articles by Matsumoto, Y.

Impaired Antibody-dependent Cellular Cytotoxicity Mediated by Herceptin in Patients with Gastric Cancer¹

First Department of Surgery, Yamanashi Medical University, Yamanashi 409-3898, Japan

The humanized monoclonal antibody Herceptin, which specifically targets HER-2/neu, exhibits growth inhibitory activity against HER-2/neu-overexpressing tumors and is approved for therapeutic use with proved survival benefit in patients with HER-2/neu-positive breast cancer. In the present study, we investigated whether Herceptin could affect the HER-2/neu-overexpressing gastric cancer cells based on antibody-dependent cell-mediated cytotoxicity (ADCC) and compared immune effector cells from gastric cancer patients with normal individuals on ADCC. HER-2/neu-expressing gastric cancer cells could be killed by Herceptin-mediated ADCC and the Herceptin-induced ADCC correlated with the degree of HER-2/neu expression on the gastric cancer cells. However, the Herceptin-mediated ADCC was significantly impaired in peripheral blood mononuclear cells from advanced disease patients (n = 10) compared with that in early disease (n = 12; P = 0.04) or healthy individuals (n = 10, P = 0.02). Moreover, natural killer (NK) cells purified from patients with advanced disease indicated less Herceptin-mediated ADCC in comparison with that from healthy donors (P = 0.04), whereas monocytes purified from the patients showed an almost equal amount of Herceptin-mediated ADCC in comparison with that from healthy individuals, indicating that NK cell dysfunction contributed to the impaired Herceptin-mediated ADCC in gastric cancer patients. Furthermore, the NK-cell dysfunction on Herceptin-mediated ADCC correlated with the down-regulation of CD16 expression in the patients, and interleukin 2 ex vivo treatment of NK cells could restore the impairment of Herceptin-mediated ADCC, concomitant to the normalization of the expression of CD16 molecules. Thus, some modalities such as interleukin 2 treatment aimed at reversing NK dysfunction may be necessary for successful Herceptin treatment of gastric cancer.

This article has been cited by other articles:

				Y. KAWAGUCHI, K. KONO, Y. MIZUKAMI, K. MIMURA, and H. FUJII Mechanisms of Escape from Trastuzumab-mediated ADCC in Esophageal Squamous Cell Carcinoma: Relation to Susceptibility to Perforin-granzyme Anticancer Res, June 1, 2009; 29(6): 2137 - 2146. [Abstract] [Full Text] [PDF]

				R. Kinders, R. E. Parchment, J. Ji, S. Kummar, A. J. Murgo, M. Gutierrez, J. Collins, L. Rubinstein, O. Pickeral, S. M. Steinberg, et al. Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice Mol. Interv., December 1, 2007; 7(6): 325 - 334. [Abstract] [Full Text] [PDF]

				M. Barok, J. Isola, Z. Palyi-Krekk, P. Nagy, I. Juhasz, G. Vereb, P. Kauraniemi, A. Kapanen, M. Tanner, G. Vereb, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance Mol. Cancer Ther., July 1, 2007; 6(7): 2065 - 2072. [Abstract] [Full Text] [PDF]

				K. Mimura, K. Kono, M. Hanawa, M. Kanzaki, A. Nakao, A. Ooi, and H. Fujii Trastuzumab-Mediated Antibody-Dependent Cellular Cytotoxicity against Esophageal Squamous Cell Carcinoma Clin. Cancer Res., July 1, 2005; 11(13): 4898 - 4904. [Abstract] [Full Text] [PDF]

				K. Motoki, E. Mori, A. Matsumoto, M. Thomas, T. Tomura, R. Humphreys, V. Albert, M. Muto, H. Yoshida, M. Aoki, et al. Enhanced Apoptosis and Tumor Regression Induced by a Direct Agonist Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 2 Clin. Cancer Res., April 15, 2005; 11(8): 3126 - 3135. [Abstract] [Full Text] [PDF]

				M. D. Pegram Molecular Determinants of Trastuzumab Response/Resistance Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 155 - 159. [Full Text] [PDF]

				X.-F. Le, A. Lammayot, D. Gold, Y. Lu, W. Mao, T. Chang, A. Patel, G. B. Mills, and R. C. Bast Jr. Genes Affecting the Cell Cycle, Growth, Maintenance, and Drug Sensitivity Are Preferentially Regulated by Anti-HER2 Antibody through Phosphatidylinositol 3-Kinase-AKT Signaling J. Biol. Chem., January 21, 2005; 280(3): 2092 - 2104. [Abstract] [Full Text] [PDF]

				R. Stein and D. M. Goldenberg A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy Mol. Cancer Ther., December 1, 2004; 3(12): 1559 - 1564. [Abstract] [Full Text] [PDF]

				K. Kono, E. Sato, H. Naganuma, A. Takahashi, K. Mimura, H. Nukui, and H. Fujii Trastuzumab (Herceptin) Enhances Class I-Restricted Antigen Presentation Recognized by HER-2/neu-Specific T Cytotoxic Lymphocytes Clin. Cancer Res., April 1, 2004; 10(7): 2538 - 2544. [Abstract] [Full Text] [PDF]